Corbus Pharmaceuticals (CRBP) Corporate presentation summary

Pipeline overview and financials

• Two lead assets: CRB-701 (Nectin-4 ADC for solid tumors) and CRB-913 (peripherally restricted CB1 inverse agonist for obesity).

• CRB-701 in Phase 2/3 for cervical cancer and Phase 2 for metastatic urothelial carcinoma; FDA Fast Track for HNSCC and cervical cancer.

• CRB-913 advancing in obesity, with a 16-week dose-range study (n=240) expected summer 2026.

• Cash and equivalents of $138M as of March 31, 2026; ~17.7M shares outstanding.

CRB-701: Clinical data and efficacy in OPSCC and cervical cancer

• In OPSCC, 3.6 mg/kg Q3W dose showed 42.9% confirmed objective response rate (CORR) and 85.7% disease control rate (DCR).

• Median duration of response (DoR) was 6.3 months and progression-free survival (PFS) was 5.6 months in OPSCC.

• Non-OPSCC HNSCC showed 0% CORR and 62.5% DCR at 3.6 mg/kg.

• Cervical cancer at 3.6 mg/kg achieved 34.4% CORR, 75% DCR, 8.0 months DoR, and 4.3 months PFS.

• CRB-701 demonstrated favorable safety, with low rates of peripheral neuropathy (7.3%, all grade 1/2), manageable ocular toxicity, and few discontinuations.

Market opportunity and competitive context

• OPSCC incidence rising due to increased HPV+ cases; HPV+ now 57% of HNSCC in the US.

• Cervical cancer market in the US is $1.8B, with 14,000 new cases and 4,000 deaths annually.

• Tivdak® (tisotumab vedotin) is current 2L standard for cervical cancer, with 17.8% ORR and $328M annualized global sales.

• CRB-701 shows higher efficacy and favorable safety compared to Tivdak® and other competitors in 2L cervical cancer.